Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

J.A. Cohen, A.J. Coles, D.L. Arnold, C. Confavreux, E.J. Fox, H.P. Hartung, E. Havrdova, K.W. Selmaj, H.L. Weiner, E. Fisher, V.V. Brinar, G. Giovannoni, M. Stojanovic, B.I. Ertik, St.L. Lake, D.H. Margolin, F. Barkhof, M.A. Panzara, D. Compston

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)1819-1828
JournalLancet
Volume380
Issue number9856
DOIs
Publication statusPublished - 2012

Cite this

Cohen, J.A. ; Coles, A.J. ; Arnold, D.L. ; Confavreux, C. ; Fox, E.J. ; Hartung, H.P. ; Havrdova, E. ; Selmaj, K.W. ; Weiner, H.L. ; Fisher, E. ; Brinar, V.V. ; Giovannoni, G. ; Stojanovic, M. ; Ertik, B.I. ; Lake, St.L. ; Margolin, D.H. ; Barkhof, F. ; Panzara, M.A. ; Compston, D. / Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. In: Lancet. 2012 ; Vol. 380, No. 9856. pp. 1819-1828.
@article{c96c9c86af414ef0b36b34c3000f41e3,
title = "Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial",
author = "J.A. Cohen and A.J. Coles and D.L. Arnold and C. Confavreux and E.J. Fox and H.P. Hartung and E. Havrdova and K.W. Selmaj and H.L. Weiner and E. Fisher and V.V. Brinar and G. Giovannoni and M. Stojanovic and B.I. Ertik and St.L. Lake and D.H. Margolin and F. Barkhof and M.A. Panzara and D. Compston",
year = "2012",
doi = "10.1016/S0140-6736(12)61769-3",
language = "Undefined/Unknown",
volume = "380",
pages = "1819--1828",
journal = "Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9856",

}

Cohen, JA, Coles, AJ, Arnold, DL, Confavreux, C, Fox, EJ, Hartung, HP, Havrdova, E, Selmaj, KW, Weiner, HL, Fisher, E, Brinar, VV, Giovannoni, G, Stojanovic, M, Ertik, BI, Lake, SL, Margolin, DH, Barkhof, F, Panzara, MA & Compston, D 2012, 'Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial' Lancet, vol. 380, no. 9856, pp. 1819-1828. https://doi.org/10.1016/S0140-6736(12)61769-3

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. / Cohen, J.A.; Coles, A.J.; Arnold, D.L.; Confavreux, C.; Fox, E.J.; Hartung, H.P.; Havrdova, E.; Selmaj, K.W.; Weiner, H.L.; Fisher, E.; Brinar, V.V.; Giovannoni, G.; Stojanovic, M.; Ertik, B.I.; Lake, St.L.; Margolin, D.H.; Barkhof, F.; Panzara, M.A.; Compston, D.

In: Lancet, Vol. 380, No. 9856, 2012, p. 1819-1828.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

AU - Cohen, J.A.

AU - Coles, A.J.

AU - Arnold, D.L.

AU - Confavreux, C.

AU - Fox, E.J.

AU - Hartung, H.P.

AU - Havrdova, E.

AU - Selmaj, K.W.

AU - Weiner, H.L.

AU - Fisher, E.

AU - Brinar, V.V.

AU - Giovannoni, G.

AU - Stojanovic, M.

AU - Ertik, B.I.

AU - Lake, St.L.

AU - Margolin, D.H.

AU - Barkhof, F.

AU - Panzara, M.A.

AU - Compston, D.

PY - 2012

Y1 - 2012

U2 - 10.1016/S0140-6736(12)61769-3

DO - 10.1016/S0140-6736(12)61769-3

M3 - Article

VL - 380

SP - 1819

EP - 1828

JO - Lancet

JF - Lancet

SN - 0140-6736

IS - 9856

ER -